{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T18:10:02Z","timestamp":1748110202771,"version":"3.41.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T00:00:00Z","timestamp":1744588800000},"content-version":"vor","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100020771","name":"Young Scientists Fund of the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82101423"],"award-info":[{"award-number":["82101423"]}],"id":[{"id":"10.13039\/501100020771","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"crossref","award":["2021YFC2702001"],"award-info":[{"award-number":["2021YFC2702001"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Pediatr"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s12519-025-00901-x","type":"journal-article","created":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T15:02:15Z","timestamp":1744642935000},"page":"419-422","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tofacitinib: a promising agent for the treatment of persistent rashes in juvenile dermatomyositis"],"prefix":"10.1007","volume":"21","author":[{"given":"Zhao-Yu","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tian-Nan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen-Jie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9801-2517","authenticated-orcid":false,"given":"Hong-Mei","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,14]]},"reference":[{"key":"901_CR1","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1002\/art.40060","volume":"69","author":"LG Rider","year":"2017","unstructured":"Rider LG, Aggarwal R, Pistorio A, Bayat N, Erman B, Feldman BM, et al. 2016 American college of rheumatology\/European league against rheumatism criteria for minimal, moderate, and major clinical response in juvenile dermatomyositis: an international myositis assessment and clinical studies group\/paediatric rheumatology international trials organisation collaborative initiative. Arthritis Rheumatol. 2017;69:911\u201323.","journal-title":"Arthritis Rheumatol"},{"key":"901_CR2","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1136\/annrheumdis-2016-209247","volume":"76","author":"F Bellutti Enders","year":"2017","unstructured":"Bellutti Enders F, Bader-Meunier B, Baildam E, Constantin T, Dolezalova P, Feldman BM, et al. Consensus-based recommendations for the management of juvenile dermatomyositis. Ann Rheum Dis. 2017;76:329\u201340.","journal-title":"Ann Rheum Dis"},{"key":"901_CR3","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S0140-6736(15)01021-1","volume":"387","author":"N Ruperto","year":"2016","unstructured":"Ruperto N, Pistorio A, Oliveira S, Zulian F, Cuttica R, Ravelli A, et al. Paediatric Rheumatology International Trials Organisation (PRINTO). Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. Lancet. 2016;387:671\u20138.","journal-title":"Lancet"},{"key":"901_CR4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s12519-019-00313-8","volume":"16","author":"JQ Wu","year":"2020","unstructured":"Wu JQ, Lu MP, Reed AM. Juvenile dermatomyositis: advances in clinical presentation, myositis-specific antibodies and treatment. World J Pediatr. 2020;16:31\u201343.","journal-title":"World J Pediatr"},{"key":"901_CR5","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1002\/art.40418","volume":"70","author":"CT Deakin","year":"2018","unstructured":"Deakin CT, Campanilho-Marques R, Simou S, Moraitis E, Wedderburn LR, Pullenayegum E, et al. Efficacy and safety of cyclophosphamide treatment in severe juvenile dermatomyositis shown by marginal structural modeling. Arthritis Rheumatol. 2018;70:785\u201393.","journal-title":"Arthritis Rheumatol"},{"key":"901_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102997","volume":"21","author":"RP Goswami","year":"2022","unstructured":"Goswami RP, Haldar SN, Chatterjee M, Vij P, van der Kooi AJ, Lim J, et al. Efficacy and safety of intravenous and subcutaneous immunoglobulin therapy in idiopathic inflammatory myopathy: a systematic review and meta-analysis. Autoimmun Rev. 2022;21:102997.","journal-title":"Autoimmun Rev"},{"key":"901_CR7","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13075-020-02164-5","volume":"22","author":"R Campanilho-Marques","year":"2020","unstructured":"Campanilho-Marques R, Deakin CT, Simou S, Papadopoulou C, Wedderburn LR, Pilkington CA, et al. Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients. Arthritis Res Ther. 2020;22:79.","journal-title":"Arthritis Res Ther"},{"key":"901_CR8","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1093\/rheumatology\/keac399","volume":"62","author":"B Huang","year":"2023","unstructured":"Huang B, Wang X, Niu Y, Ding Y, Wang X, Tan Q, et al. Long-term follow-up of Janus-kinase inhibitor and novel active disease biomarker in juvenile dermatomyositis. Rheumatology. 2023;62:1227\u201337.","journal-title":"Rheumatology"},{"key":"901_CR9","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1093\/rheumatology\/keaa558","volume":"60","author":"Z Yu","year":"2021","unstructured":"Yu Z, Wang L, Quan M, Zhang T, Song H. Successful management with Janus kinase inhibitor tofacitinib in refractory juvenile dermatomyositis: a pilot study and literature review. Rheumatology. 2021;60:1700\u20137.","journal-title":"Rheumatology"},{"key":"901_CR10","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1136\/annrheumdis-2020-218582","volume":"80","author":"Y Ding","year":"2021","unstructured":"Ding Y, Huang B, Wang Y, Hou J, Chi Y, Zhou Z, et al. Janus kinase inhibitor significantly improved rash and muscle strength in juvenile dermatomyositis. Ann Rheum Dis. 2021;80:543\u20135.","journal-title":"Ann Rheum Dis"},{"key":"901_CR11","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3899\/jrheum.160688","volume":"44","author":"A Huber","year":"2017","unstructured":"Huber A, Kim S, Reed A, Carrasco R, Feldman B, Hong S, et al.; Juvenile Dermatomyositis Research Committee of the Childhood Arthritis and Rheumatology Research Alliance. Childhood arthritis and rheumatology research alliance consensus clinical treatment plans for juvenile dermatomyositis with persistent skin rash. J Rheumatol. 2017;44:110\u20136.","journal-title":"J Rheumatol"},{"key":"901_CR12","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1056\/NEJM197502132920706","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292:344\u20137.","journal-title":"N Engl J Med"},{"key":"901_CR13","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJM197502202920807","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292:403\u20137.","journal-title":"N Engl J Med"},{"key":"901_CR14","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1007\/s12016-020-08786-6","volume":"59","author":"H You","year":"2020","unstructured":"You H, Xu D, Zhao J, Li J, Wang Q, Tian X, et al. JAK inhibitors: prospects in connective tissue diseases. Clin Rev Allergy Immunol. 2020;59:334\u201351.","journal-title":"Clin Rev Allergy Immunol"},{"key":"901_CR15","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S0140-6736(15)01021-1","volume":"387","author":"N Ruperto","year":"2016","unstructured":"Ruperto N, Pistorio A, Oliveira S, Zulian F, Cuttica R, Ravelli A, et al. Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. Lancet. 2016;387:671\u20138.","journal-title":"Lancet"},{"key":"901_CR16","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1097\/BOR.0000000000000816","volume":"33","author":"H Kim","year":"2021","unstructured":"Kim H. Updates on interferon in juvenile dermatomyositis: pathogenesis and therapy. Curr Opin Rheumatol. 2021;33:371\u20137.","journal-title":"Curr Opin Rheumatol"},{"key":"901_CR17","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1093\/rheumatology\/kew288","volume":"55","author":"L Ekholm","year":"2016","unstructured":"Ekholm L, Kahlenberg JM, Barbasso Helmers S, Tj\u00e4rnlund A, Yalavarthi S, Zhao W, et al. Dysfunction of endothelial progenitor cells is associated with the type I IFN pathway in patients with polymyositis and dermatomyositis. Rheumatology (Oxford). 2016;55:1987\u201392.","journal-title":"Rheumatology (Oxford)"},{"key":"901_CR18","doi-asserted-by":"publisher","first-page":"394","DOI":"10.55563\/clinexprheumatol\/56ilob","volume":"40","author":"LJ McCann","year":"2022","unstructured":"McCann LJ, Livermore P, Wilkinson MGL, Wedderburn LR. Juvenile dermatomyositis. where are we now? Clin Exp Rheumatol. 2022;40:394\u2013403.","journal-title":"Clin Exp Rheumatol"},{"key":"901_CR19","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1093\/brain\/awz293","volume":"142","author":"S Sabbagh","year":"2019","unstructured":"Sabbagh S, Almeida de Jesus A, Hwang S, Kuehn HS, Kim H, Jung L, et al. Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib. Brain. 2019;142:e59.","journal-title":"Brain"},{"key":"901_CR20","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/s13075-023-03170-z","volume":"25","author":"J Zhang","year":"2023","unstructured":"Zhang J, Sun L, Shi X, Li S, Liu C, Li X, et al. Janus kinase inhibitor, tofacitinib, in refractory juvenile dermatomyositis: a retrospective multi-central study in China. Arthritis Res Ther. 2023;25:204.","journal-title":"Arthritis Res Ther"},{"key":"901_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2024.152426","volume":"66","author":"S Sener","year":"2024","unstructured":"Sener S, Cam V, Ozen S, Batu ED. Treatment with Janus kinase inhibitors in juvenile dermatomyositis: a review of the literature. Semin Arthritis Rheum. 2024;66:152426.","journal-title":"Semin Arthritis Rheum"}],"container-title":["World Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12519-025-00901-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12519-025-00901-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12519-025-00901-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T17:36:06Z","timestamp":1748108166000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12519-025-00901-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["901"],"URL":"https:\/\/doi.org\/10.1007\/s12519-025-00901-x","relation":{},"ISSN":["1708-8569","1867-0687"],"issn-type":[{"type":"print","value":"1708-8569"},{"type":"electronic","value":"1867-0687"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"9 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no financial or non-financial conflict of interest. Hong-Mei Song is an Editorial Board for\u00a0the journal of World Journal of Pediatrics. The paper was handled by other Editors and has undergone a rigorous peer review process. Author Hong-Mei Song was not involved in the journal\u2019s review or decisions making of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (ZS-2144). Written informed consent was obtained from the guardians of all patients before treatment commenced.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}